Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DSGNNASDAQ:FDMTNASDAQ:IFRXNASDAQ:SCPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDSGNDesign Therapeutics$3.84-1.8%$3.74$2.60▼$7.77$217.99M1.62183,116 shs65,992 shsFDMT4D Molecular Therapeutics$4.39-2.4%$3.45$2.24▼$28.93$203.37M2.84829,202 shs486,407 shsIFRXInflaRx$0.78-2.0%$1.28$0.71▼$2.82$52.63M1.29283,348 shs819,458 shsSCPHscPharmaceuticals$3.95-1.3%$2.99$1.94▼$5.65$208.53M0.36369,031 shs211,100 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDSGNDesign Therapeutics-1.79%-4.24%+19.63%-18.30%+1.86%FDMT4D Molecular Therapeutics-2.44%+0.92%+40.26%+6.81%-81.76%IFRXInflaRx-2.00%-5.55%-57.39%-34.12%-50.69%SCPHscPharmaceuticals-1.25%-5.95%+76.34%+30.36%-2.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDSGNDesign Therapeutics0.6473 of 5 stars1.01.00.00.02.72.50.6FDMT4D Molecular Therapeutics2.8834 of 5 stars3.33.00.00.04.01.70.6IFRXInflaRx3.388 of 5 stars4.53.00.00.02.21.70.6SCPHscPharmaceuticals4.4377 of 5 stars3.54.00.04.23.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDSGNDesign Therapeutics 2.00Hold$4.004.17% UpsideFDMT4D Molecular Therapeutics 2.60Moderate Buy$29.56573.25% UpsideIFRXInflaRx 3.00Buy$6.60741.84% UpsideSCPHscPharmaceuticals 3.00Buy$14.00254.43% UpsideCurrent Analyst Ratings BreakdownLatest IFRX, DSGN, SCPH, and FDMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)5/29/2025IFRXInflaRxRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$2.005/29/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$6.00 ➝ $3.005/24/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/10/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/9/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $25.005/9/2025FDMT4D Molecular TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $44.005/9/2025FDMT4D Molecular TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $38.005/8/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.004/29/2025IFRXInflaRxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.004/24/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDSGNDesign TherapeuticsN/AN/AN/AN/A$4.96 per shareN/AFDMT4D Molecular Therapeutics$23K8,842.03N/AN/A$7.20 per share0.61IFRXInflaRx$129.75K405.64N/AN/A$1.89 per share0.41SCPHscPharmaceuticals$41.98M4.97N/AN/A$1.04 per share3.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDSGNDesign Therapeutics-$66.86M-$0.99N/AN/AN/AN/A-18.01%-17.38%8/4/2025 (Estimated)FDMT4D Molecular Therapeutics-$100.84M-$3.18N/AN/AN/AN/A-28.00%-26.16%8/14/2025 (Estimated)IFRXInflaRx-$46.18M-$0.82N/AN/AN/A-33,362.70%-65.98%-56.86%8/6/2025 (Estimated)SCPHscPharmaceuticals-$54.81M-$1.91N/AN/AN/A-264.60%-244.93%-68.56%8/13/2025 (Estimated)Latest IFRX, DSGN, SCPH, and FDMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/A5/14/2025Q1 2025SCPHscPharmaceuticals-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 million5/8/2025Q1 2025FDMT4D Molecular Therapeutics-$0.84-$0.86-$0.02-$0.86$0.53 millionN/A5/7/2025Q1 2025IFRXInflaRx-$0.18-$0.14+$0.04-$0.14$0.03 million$0.03 million3/20/2025Q4 2024IFRXInflaRx-$0.27-$0.09+$0.18-$0.09$0.13 millionN/A3/19/2025Q4 2024SCPHscPharmaceuticals-$0.40-$0.35+$0.05-$0.35$12.08 million$12.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDSGNDesign TherapeuticsN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDSGNDesign TherapeuticsN/A34.6134.61FDMT4D Molecular TherapeuticsN/A17.3317.33IFRXInflaRxN/A5.314.61SCPHscPharmaceuticals1.668.086.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDSGNDesign Therapeutics56.64%FDMT4D Molecular Therapeutics99.27%IFRXInflaRx42.39%SCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipDSGNDesign Therapeutics31.20%FDMT4D Molecular Therapeutics9.60%IFRXInflaRx16.30%SCPHscPharmaceuticals4.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDSGNDesign Therapeutics4056.77 million38.96 millionOptionableFDMT4D Molecular Therapeutics12046.33 million42.85 millionOptionableIFRXInflaRx6067.13 million56.19 millionOptionableSCPHscPharmaceuticals3052.79 million47.28 millionOptionableIFRX, DSGN, SCPH, and FDMT HeadlinesRecent News About These CompaniesWith 42% stake, scPharmaceuticals Inc. (NASDAQ:SCPH) seems to have captured institutional investors' interestJune 12 at 10:31 AM | finance.yahoo.comNuveen Asset Management LLC Has $320,000 Position in scPharmaceuticals Inc. (NASDAQ:SCPH)June 6, 2025 | marketbeat.comBNP Paribas Financial Markets Increases Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)May 29, 2025 | marketbeat.comWoodline Partners LP Sells 203,808 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)May 28, 2025 | marketbeat.comscPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025May 22, 2025 | seekingalpha.comStonepine Capital Management LLC Has $2.42 Million Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)May 20, 2025 | marketbeat.comLeerink Partnrs Analysts Lower Earnings Estimates for SCPHMay 20, 2025 | marketbeat.comSuvretta Capital Management LLC Reduces Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)May 19, 2025 | marketbeat.comscPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 16, 2025 | finance.yahoo.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectoryMay 16, 2025 | msn.comScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectoryMay 16, 2025 | msn.comQ1 2025 scPharmaceuticals Inc Earnings CallMay 16, 2025 | finance.yahoo.comQ1 2025 scPharmaceuticals Inc Earnings CallMay 16, 2025 | finance.yahoo.comWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%May 16, 2025 | aaii.comWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%May 16, 2025 | aaii.comscPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue EstimatesMay 14, 2025 | zacks.comscPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | globenewswire.comscPharmaceuticals Inc. (NASDAQ:SCPH) Stake Reduced by J. Goldman & Co LPMay 14, 2025 | marketbeat.comInsights Ahead: scPharmaceuticals's Quarterly EarningsMay 13, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIFRX, DSGN, SCPH, and FDMT Company DescriptionsDesign Therapeutics NASDAQ:DSGN$3.84 -0.07 (-1.79%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.84 +0.01 (+0.13%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.4D Molecular Therapeutics NASDAQ:FDMT$4.39 -0.11 (-2.44%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.40 +0.02 (+0.34%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.InflaRx NASDAQ:IFRX$0.78 -0.02 (-2.00%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.78 0.00 (-0.38%) As of 06/13/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.scPharmaceuticals NASDAQ:SCPH$3.95 -0.05 (-1.25%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.10 +0.15 (+3.67%) As of 06/13/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
